[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622806":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":33,"responsibleParty":66,"collaborators":68,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":10,"eligibilityCriteria":77,"healthyVolunteers":73,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":84,"studyType":85,"phases":10,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Foundation University Islamabad","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"RA patients taking Leflunomide",null,"RA patients in Pakistani population taking Leflunomide as a single DMARD",[13],"Drug: Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients",[9],[20],{"name":21,"affiliation":5,"role":22},"Prof Muzammil Hassan Najmi","STUDY_DIRECTOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Dr. Zarafshan Bader, MPhil, MBBS","CONTACT","0923005177254","zarafshan.bader@fui.edu.pk",{"name":30,"role":26,"phone":10,"phoneExt":31,"email":32},"Dr Abida Shaheen, PHD, MBBS, FAIMER FELLOW","0923215900346","abida.scm@stmu.edu.pk",[34,48],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"Shifa International Hospital","COMPLETED","Islamabad","Punjab Province","44000","Pakistan","PK",{"type":43,"coordinates":44},"Point",[45,46],74.4039,31.6047,{"lat":46,"lon":45},{"facility":49,"status":50,"city":51,"state":38,"zip":52,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Fauji Foundation Hospital, Rawalpindi","RECRUITING","Rawalpindi","46000",{"type":43,"coordinates":54},[55,56],73.0479,33.59733,{"lat":56,"lon":55},[59,63],{"name":60,"role":26,"phone":61,"phoneExt":10,"email":62},"Saba Samreen, FCPS","+923145296060","sabasamreen@hotmail.com",{"name":64,"role":65,"phone":10,"phoneExt":10,"email":10},"Zarafshan Bader, M Phil","PRINCIPAL_INVESTIGATOR",{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[69],{"name":70,"class":6},"Shifa Tameer-e-Millat University","100622806","pharmacogenetics-of-leflunomide-in-the-management-of-rheumatoid-arthritis-100622806",false,"NCT07388407","Pharmacogenetics of Leflunomide in the Management of Rheumatoid Arthritis","Pharmacogenetics of Leflunomide in the RA Management","Inclusion Criteria:\n\n* At baseline, all patients should fulfill the revised ACR\u002FEULAR criteria for RA10\n* Pakistani individuals\n* between ages of 20-75 years\n* New cases started on Leflunomide\u002F those already taking for less than a month and their biochemical and clinical data is available\n\nExclusion Criteria:\n\n* Patients not willing to participate\u002F consent not given\n* Patients below the age of 20\n* Non- Pakistani origin\n* Taking another DMARD simultaneously\n* Compromised renal and hepatic functions\n* Cognitive impairment, neurological disease\n* Pregnant\u002F lactating patients\n* Patients having inflammatory bowel disease\u002F Irritable bowel syndrome\n* Patients with active infective diseases -Patients who fail to complete 3 months of leflunomide therapy-","ALL","20 Years","65 Years",{"count":82,"type":83},110,"ESTIMATED","2 Months","OBSERVATIONAL","1. Patients taking leflunomide as the only disease-modifying anti-rheumatic drug (DMARD) will be recruited after consent.\n2. Blood sample for DNA extraction will be taken The patient will be followed up till two visits 3 months apart, and efficacy and toxicity will be checked using DAS28, ultrasonography, and blood tests for ESR, CRP, anti-CCP, liver function tests, etc. The data form for toxicity will be filled.\n3. DNA will be extracted in the laboratory, and SNP will be identified.\n4. The efficacy and toxicity data will be studied against the SNPs found\n5. An algorithm will be constructed for Pakistani RA patients taking leflunomide.",[88],"Rhematoid Arthritis",[90,91,92],"RA","SNP","Leflunomide","2026-01-30",{"date":95,"type":96},"2026-02-05","ACTUAL",{"date":98,"type":96},"2024-09-01",{"date":100,"type":83},"2026-09-30",{"name":5,"class":6},2]